Blue Sail Medical to Divest Emergency Care Business to Sharpen Strategic Focus and Advance High-Quality Growth

Source: Xinhua Finance

December 30,Bluesail MedicalAnnouncement hinted that the company plans to sell Wuhan Bicare Rescue Products Co., Ltd. ("Bicare"), the main body of its emergency rescue business segment, to Wuhan.EasyDiagnosisBluesail Medical Co., Ltd. According to the announcement, in order to further focus on core businesses, increase cash reserves, revitalize existing assets, and shorten the management radius, Bluesail Medical plans to sell all the equity of its wholly-owned subsidiary, Wuhan Bicare Rescue Products Co., Ltd., for cash consideration.

This transaction marks a key step forward in Bluesail Medical's strategic focus on core businesses and optimization of its asset structure. Upon completion, the deal will not only strengthen the company’s financial foundation and enhance its debt repayment capabilities, but also fully unlock asset value to achieve mutual benefits with EasyDiagnosis, setting a practical example for optimizing resource allocation in the healthcare sector. As another significant strategic move following the introduction of Thai investment into the health protection segment, this transaction fully demonstrates the depth of the company’s asset value, its firm determination and strong capability to proactively manage debt, creating opportunities for the long-term development of its core business.

Divest Non-Core Businesses: Asset Structure Optimization Upgrade

The sale of BrioHealth Solutions represents an important practice for the company to focus on its core business and continuously optimize asset allocation. Data shows that BrioHealth Solutions has been deeply engaged in the emergency medical field for many years. It was one of the earlier enterprises in China to introduce the international First Aid concept and technology. Its product portfolio comprehensively covers diverse scenarios such as home, automotive, commercial, industrial, outdoor, business travel, and disaster relief. Meanwhile, it has established stable channel distribution in overseas markets, demonstrating outstanding market competitiveness.

In the long term, emergency rescue, like the cardiovascular and cerebrovascular and health protection sectors, has broad market potential. However, this division is constrained by factors such as management scope and resource allocation, making it difficult to continuously reflect its internal value within Bluesail Medical.

As Bluesail Medical deepens its strategic focus on high-growth businesses in cardiovascular and cerebrovascular fields, as well as the traditional cornerstone business of health protection, the emergency rescue operations in Hubei have become less synergistic with the company’s core development direction. Divesting this business has thus become an inevitable choice to optimize resource allocation. By selling Bicare to EasyDiagnosis, Bluesail Medical has been able to further shorten its management radius, reduce operational complexity, and concentrate resources on core businesses, effectively improving efficiency, streamlining internal management functions, and strengthening core competitiveness. This move also reduces market concerns about the company's diversified operations while providing a replicable success model for subsequent asset structure optimization and the tapping of existing assets.

Bluesail Medical's Potential for Asset Optimization in the Near Future Goes Beyond This. Recently, the official website of the Shanghai Stock Exchange showed that the Sci-Tech Innovation Board IPO application of BrioHealth Solutions, in which Bluesail Medical holds a 4.88% stake, has been accepted. If BrioHealth Solutions successfully goes public, the company will acquire more liquid equity assets. Meanwhile, with the increase in value of BrioHealth Solutions after its listing, the equity is expected to appreciate significantly. The company can recognize investment income through fair value changes, further boosting its performance.

Recycling Funds to Alleviate Debt Pressure and Strengthen Financial Development Foundation

This asset disposal is also a key strategic move for the company to proactively optimize its financial structure and alleviate debt pressure. Through market-oriented asset operations, the company has not only effectively mitigated short-term liquidity risks but also laid a solid financial foundation for long-term stable development. This effort continuously improves the financial situation, strengthens operational resilience, and boosts confidence in the capital markets across the board.

The most direct effect of this move is to revitalize high-quality assets and recover funds, significantly bolstering the company’s cash reserves, providing solid support for mitigating short-term debt risks. The cash flow generated from the transaction will enhance the company's liquidity, offering strong financial assurance for debt repayment, and achieving precise resolution of short-term risks.

In the long term, a more substantial cash reserve also provides stable financial support for R&D investment, capacity upgrades, and market expansion in core businesses such as cardiovascular and cerebrovascular health and protective healthcare. This helps the company focus on its main business, accelerate the iteration of core products, and inject lasting momentum into long-term high-quality development.

Notably, this transaction represents another significant practice in optimizing the company's financial condition through market-oriented operations, following the introduction of Thai strategic investors into the health protection sector. It fully demonstrates the firm determination and efficient execution of the company's management to proactively address debt issues and improve operational quality. Through a series of precise asset operations and strategic layouts, the company continues to resolve operational challenges, strengthen its financial foundation, and effectively enhance its risk resistance capabilities.

Moreover, for EasyDiagnosis, it shares the same location in Wuhan with BrioHealth Solutions, boasting significant geographical advantages and lower communication costs. After the acquisition, EasyDiagnosis can quickly integrate BrioHealth Solutions' mature emergency product portfolio, well-established B-end customer system, and overseas channel resources. This will promote its integrated critical care business to extend from medical institutions to industrial and home scenarios, building a "diagnosis-protection-treatment" collaborative ecosystem, and further consolidating and enhancing its market position and comprehensive competitiveness in the critical care field.

This transaction will successfully achieve the complementary advantages and mutually beneficial win-win situation between Bluesail Medical and EasyDiagnosis. Both parties will rely on their respective resource endowments to achieve coordinated development and value co-creation. (Chen Chuan)

Editor: Zhao Ding